{"url_path":"/sec/cik-0001697884/10-k/2026/item-16","section_key":"item-16","section_title":"Item 16 Form 10-K Summary**.","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","accession_number":"0001640334-26-001082","cik":"0001697884","ticker":null,"issuer_name":"VITASPRING BIOMEDICAL CO. LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","primary_entity_key":"0001697884","primary_entity_name":"VITASPRING BIOMEDICAL CO. LTD."},"word_count":139,"has_tables":true,"body_markdown":"**Item 16. Form 10-K Summary**.\n\n \n\nNone.\n\n \n\n \n\n32\n\n*Table of Contents*\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\n \n\n**VITASPRING BIOMEDICAL CO., LTD.**\n\n \n\n \n\n \n\n \n\n \n\nDate: June 17, 2026\n\n \n\n*/s/ Ssu-Chuan Lai*\n\n \n\n \n\n \n\nSsu-Chuan Lai\n\n \n\n \n\n \n\nDirector, President and Chief Executive Officer (Principal Executive Officer,\n\nPrincipal Financial Officer and Principal Accounting Officer)\n\n \n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities on the dates indicated.\n\n \n\n \n\n \n\n**VITASPRING BIOMEDICAL CO., LTD.**\n\n \n\n \n\n \n\n \n\n \n\nDate: June 17, 2026\n\n \n\n*/s/ Ssu-Chuan Lai*\n\n \n\n \n\n \n\nSsu-Chuan Lai\n\n \n\n \n\n \n\nDirector, President and Chief Executive Officer (Principal Executive Officer,\n\nPrincipal Financial Officer and Principal Accounting Officer)\n\n \n\n \n\n \n\n33"}